People with ulcerative colitis, a form of IBD, who were taking the new drug Omvoh and achieved clinical remission after 1 ...

A once-daily pill for ulcerative colitis has delivered strong results in a clinical trial, easing symptoms even in patients ...

The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative colitis who weigh ...

Once-daily oral obefazimod met the primary endpoint of clinical remission at 8 weeks in a highly refractory population of ...

Eli Lilly’s ulcerative colitis (UC) treatment, Omvoh (mirikizumab), has shown sustained positive outcomes in patients with ...

While an individualized approach is best, these foods may support gut health in people with ulcerative colitis.

Eli Lilly's four-year LUCENT-3 study shows Omvoh maintained high remission rates and a consistent safety profile in ...

A multicenter trial from the Netherlands suggests that meticulous donor selection and anaerobic stool preparation may enhance ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy now. On October 7, Eli Lilly and Company announced ...

Johnson & Johnson's Simponi gains FDA approval for treating pediatric ulcerative colitis, expanding options for young patients with this chronic condition.

The rollout of a drug recommended by the National Institute of Health and Care Excellence is 'really exciting' news for UK ...